Hematoma Risk After Needle Electromyography in Patients Using Newer Oral Anticoagulants.
Administration, Oral
Adult
Aged
Aged, 80 and over
Anticoagulants
/ adverse effects
Dabigatran
/ adverse effects
Electromyography
/ adverse effects
Female
Hematoma
/ etiology
Humans
Male
Middle Aged
Pyrazoles
/ administration & dosage
Pyridones
/ administration & dosage
Retrospective Studies
Rivaroxaban
/ adverse effects
Warfarin
/ adverse effects
Journal
Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society
ISSN: 1537-1603
Titre abrégé: J Clin Neurophysiol
Pays: United States
ID NLM: 8506708
Informations de publication
Date de publication:
01 Jan 2021
01 Jan 2021
Historique:
pubmed:
15
11
2019
medline:
1
4
2021
entrez:
15
11
2019
Statut:
ppublish
Résumé
To assess the safety of needle electromyography in patients on non-vitamin K oral anticoagulants (NOACs) compared with warfarin. A retrospective chart review was done in patients who underwent needle electromyography studies while they were using warfarin and NOACs. After the needle electromyography, all the patients were monitored for 2 hours and ultrasound of high-risk muscle groups was done. The complications were classified based on the International Society on Thrombosis and Hemostasis definitions. Fifty-eight patients were included: 29 were using NOACs and the other 29 were on warfarin. The mean age was 59.33 ± 16 years. Hemorrhagic complications from needle electromyography were noted in 9 patients: 7 (77.7%) NOACs and 2 (22.3%) warfarin. Among them, 6 patients (66.6%) met the diagnostic criteria for Clinically Relevant Non-Major Bleeding criteria proposed by International Society on Thrombosis and Hemostasis and 3 patients (33.4%) had an asymptomatic hematoma on ultrasound evaluation. A total of 267 muscles were tested and only 9 (3.3%) muscles had hemorrhagic complications. One patient (rivaroxaban) had acute bleeding requiring pressure bandage, five patients (two apixaban, two rivaroxaban, and one warfarin) had clinical hematoma that required ice packs, and three patients (two rivaroxaban and one warfarin) had a hematoma on ultrasound of deep muscles. Patients on NOACs had minimal risk of clinically relevant hemorrhagic complications, and the risk is not significantly different from those on warfarin.
Identifiants
pubmed: 31725032
pii: 00004691-202101000-00008
doi: 10.1097/WNP.0000000000000643
doi:
Substances chimiques
Anticoagulants
0
Pyrazoles
0
Pyridones
0
apixaban
3Z9Y7UWC1J
Warfarin
5Q7ZVV76EI
Rivaroxaban
9NDF7JZ4M3
Dabigatran
I0VM4M70GC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
69-72Informations de copyright
Copyright © 2019 by the American Clinical Neurophysiology Society.
Déclaration de conflit d'intérêts
The authors have no funding or conflicts of interest to disclose.
Références
London ZN. Safety and pain in electrodiagnostic studies. Muscle Nerve 2017;55:149–159.
American Association of Electrodiagnostic Medicine. Guidelines in electrodiagnostic medicine. Risks in electrodiagnostic medicine. Muscle Nerve Suppl 1999;8:S53.
Al-Shekhlee A, Shapiro BE, Preston DC. Iatrogenic complications and risks of nerve conduction studies and needle electromyography. Muscle Nerve 2003;27:517–526.
Boon AJ, Gertken JT, Watson JC, et al. Hematoma risk after needle electromyography. Muscle Nerve 2012;45:9–12.
Staerk L, Fosbøl EL, Gadsbøll K, Sindet-Pedersen C, et al. Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: temporal trends 2011–2015 in Denmark. Scientific Rep 2016;6:31477.
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–992.
Bansilal S, Bloomgarden Z, Halperin JL, Hellkamp AS, Lokhnygina Y, et al. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF trial). Am Heart J 2015;170:675–682.
Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, et al. Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 2016;388:1995–2003.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–1151.
Lynch SL, Boon AJ, Smith J, Harper CM Jr, Tanaka EM. Complications of needle electromyography: hematoma risk and correlation with anticoagulation and antiplatelet therapy. Muscle Nerve 2008;38:1225–1230.
Preston DC, Shapiro BE. Electromyography and neuromuscular disorders E-book: Clinical-electrophysiologic correlations (expert consult-online) St Louis: Elsevier Health Sciences, 2012.
Kaatz S, Ahmad D, Spyropoulos AC, Schulman S; Subcommittee on Control ofAnticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015;13:2119–2126.
Lee I, Kushlaf H. Needle electromyography practice patterns in patients taking novel oral anticoagulants: a survey-based study. Muscle Nerve 2018;58:307–309.
Favaloro EJ, Pasalic L, Curnow J, Lippi G. Laboratory monitoring or measurement of direct oral anticoagulants (DOACs): advantages, limitations and future challenges. Curr Drug Metab 2017;18:598–608.
Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc 2016;5:e003725.
Raval AN, Cigarroa JE, Chung MK, et al. Management of patients on non–vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association. Circulation 2017;135:e604–e633.
London Z, Quint DJ, Haig AJ, Yamakawa KS. The risk of hematoma following extensive electromyography of the lumbar paraspinal muscles. Muscle Nerve 2012;46:26–30.
Caress JB, Rutkove SB, Carlin M, Khoshbin S, Preston DC. Paraspinal muscle hematoma after electromyography. Neurology 1996;47:269–272.
Draghi F, Zacchino M, Canepari M, Nucci P, Alessandrino F. Muscle injuries: ultrasound evaluation in the acute phase. J Ultrasound 2013;16:209–214.